Platform run 2 of architecture 5, as the author pasted it on 2026-11-08 (score not reported; the platform's determinism check returned the golden, runs/determinism_finding.md).

Response 2
Reviewed 90 resources· 23m
Recommendation. Run protocol A: antipsychotic deprescribing for people aged 65 and over from April 2027.
It is expected to avoid 24 serious harms a year, compared with 12 for runner-up B, benzodiazepines and Z-drugs in people aged 65 and over. The gap is 12 additional serious harms avoided annually, calculated before rounding. This follows the programme’s rule to select the review with the greatest expected harm reduction.
Final answers. The results and paired chart are on page 1 of `medicines_safety_review_2027.pdf`; the calculation and sensitivity analysis are on page 2.

* A: Antipsychotics, age 65+. 240 patients taken off medicine; 24 serious harms avoided annually.
* B: Benzodiazepines and Z-drugs, age 65+. 280 patients taken off medicine; 12 serious harms avoided annually.
* C: Gabapentinoids taken with an opioid. 460 patients taken off medicine; 11 serious harms avoided annually.
* Recommended review: A. Runner-up: B. Annual gap: 12 serious harms.

Patient estimates are rounded to the nearest 10 and harms to whole numbers. The chart places cessation and harm reduction beside each other, with clearly separated units and scales.
Hospital medicine letters received per 1,000 patients registered at the beginning of each half-year are reported on page 3 of the PDF:

* Clun Valley: H1 46.8; H2 43.3.
* Severn Gorge: H1 44.1; H2 40.4.
* Teme Valley: H1 46.5; H2 40.6.
* Wrekinside Central: H1 43.0; H2 37.4.
* Wrekinside North: H1 43.6; H2 41.7.

The federation received 18,826 qualifying letters: 9,867 in January-June and 8,959 in July-December. The PDF also includes each network’s exact letter counts and period-start denominators.
Patient consultations per 1,000 patients registered at the beginning of each quarter are provided in `pharmacist_consultations_2026.csv`, column `consultations_per_1000_registered_patients`, and summarized on page 3 of the PDF:

* Clun Valley: Q1 13.4; Q2 13.8; Q3 13.8; Q4 13.9.
* Severn Gorge: Q1 12.7; Q2 10.8; Q3 13.6; Q4 12.7.
* Teme Valley: Q1 14.6; Q2 13.4; Q3 14.4; Q4 12.9.
* Wrekinside Central: Q1 12.3; Q2 11.2; Q3 11.5; Q4 11.1.
* Wrekinside North: Q1 13.2; Q2 12.1; Q3 12.4; Q4 11.8.

The CSV contains 20 network-quarter rows, including exact consultation counts, published registration denominators, period-start dates and the board recommendation. The federation recorded 11,233 consultations.
Step-by-step process.

1. Read all supplied evidence. Inspected all 18 files inside `ETL Build Problems Target (17).zip`. The programme specification supplied the decision rule, age-specific harm rates and activity definitions. The review protocols supplied eligibility and exclusion criteria. The Clun Valley close-out report supplied the pilot’s published cessation method and subgroup results. Page 5 of the PDF inventories every input and its use.
2. Assemble the eligibility data. Read `member_practice_register_2026.csv` for practice-to-network membership; `patient_registrations_2020-2026.parquet` for 317,930 registration spells; `prescribing_issues_2025-07_2026-12.parquet` for 287,970 actual issues; and `problem_list_extract_2026-12-31.csv` for 6,261 coded problems. Relevant source keys were unique, and the structured sources used for joins had no exact duplicate rows. Missing registration-end and death dates were not imputed.
3. Apply the programme population and search window. Selected active, living registrations on 31 December 2026, excluding Clun Valley. This produced 180,908 exact registration records across the 22 in-scope practices. Counted actual medicine issues during 1 July-31 December 2026, comprising 100,868 issue rows, and applied the protocol-specific age, medicine and diagnostic rules. A had 743 medicine-qualified records and 131 exclusions, leaving 612. B had 1,268 and 29, leaving 1,239. C had 3,193 gabapentinoid-qualified records, 1,755 also meeting the opioid threshold, and 119 exclusions, leaving 1,636. These exact audit counts are retained on page 2; the displayed eligible-patient estimates are 610, 1,240 and 1,640.
4. Validate sustained cessation against prescribing. Read `deprescribing_pilot_outcome_log_2026.csv`, containing 710 reviews and 700 follow-ups. All 700 follow-up classifications agreed with whether a class medicine was issued during days 1-183 after review. The published complete-case cessation probabilities were 64/160, 69/300 and 67/240, displayed as 40.0%, 23.0% and 27.9%. The 53 patients reissued medicine after an initial stop were counted as failures: 6 in A, 27 in B and 20 in C.
5. Calculate expected benefit. Multiplied each eligible person’s stipulated age-specific harm rate by the relevant cessation probability, then summed. The age-weighted totals before applying cessation were 60.339 for A, 51.126 for B and 38.783 for C. Expected cessation was eligible count multiplied by cessation probability. Calculations retained full precision until final presentation. A fitted prediction model was unnecessary because the programme prescribes the calculation directly.
6. Reconstruct hospital-letter receipts. Read `practice_document_workflow_2026.csv`, `trust_medicine_letters_feed_2019-2026.csv` and `trust_hospital_number_lookup.csv`. Parsed the trusts’ differing date formats explicitly. The crosswalk resolved 9,514 missing patient identifiers across 7,446 letters, with no lookup conflicts. Collapsed 176,956 medicine-line rows to 138,532 distinct letters. Exact reference matching found 15,182 receipts. After Wrekinside’s October identifier change, patient, trust, practice, document type and receipt-lag linkage recovered 4,069 further receipts using one-to-one matching. Of 19,251 matched receipts, 425 occurred in 2027 and were excluded, leaving 18,826 first receipts in 2026. No additional repeated-letter receipts remained after deduplication.
7. Reconcile patient consultations. Read `clinical_system_pharmacist_activity_2026.csv`, `pharmacist_hub_appointments_2026.csv` and the `Register` sheet of `hub_group_session_register_2026.xlsx`. Converted hub timestamps to Europe/London; 1,929 times shifted by one hour, but no calendar dates changed. Excluded 482 nonattended appointments and 25 group-session containers, retaining 2,897 attended individual hub appointments. Excluded 34 group nonattendances and retained 200 attended participants. Matched and removed 1,165 delayed clinical copies of hub encounters while preserving 151 separate same-day contact pairs. The final reconciliation was 9,301 + 2,897 + 200 - 1,165 = 11,233 consultations.
8. Attribute events and calculate rates. Assigned consultations using registration on the event date, treating registration ends as exclusive. The date-valid join reduced 13,474 candidate rows to 11,233 uniquely attributed events, with no unmatched events or conflicting practice attribution. Used `registered_list_sizes_2026.csv` for published period-start denominators, selecting 112 of its 364 practice-month rows. Quarterly federation denominators were 221,175, 221,376, 221,709 and 222,290. Rates were calculated from exact counts and rounded once to one decimal.
9. Check robustness and alternative evidence. Independent recalculation confirmed eligibility and benefit totals. Adding 30 June to the search window or applying thresholds within individual listed medicines changed no target cohort records. Age-standardization preserved the whole-number harm estimates. Conditional 95% sampling intervals were 20-29 harms for A, 10-14 for B and 9-13 for C. Letter-linkage validation recovered all 12,426 known pre-October medicine documents without false-positive or missed documents; tested receipt windows from 14 to 40 days left the reported counts unchanged. Reconstructed registrations matched every published practice denominator at the required dates.
10. Check the outputs. Opened and visually inspected all PDF pages, checked text boundaries, and re-read the CSV. Confirmed its 20 unique network-quarter rows, exact total of 11,233 consultations, one-decimal rate formatting and consistent recommendation. Removed the temporary scripts and preview image.

Assumptions and judgment calls.

* Primary cessation probabilities follow the published complete-case method. The 10 missing follow-up records concern 8 people. All had class reissues within the assessment window, so treating them as failures is also supported by the raw data. That analysis gives 23, 12 and 11 harms avoided for A, B and C, preserving the recommendation and runner-up.
* The pilot’s missing-follow-up explanation is imperfect. Five recorded deaths occurred after day 183, contrary to a blanket explanation of death before the check. This is disclosed on page 5 rather than silently accepted.
* Pilot rates are assumed transferable to the other networks. Subgroup tests and age-standardization support using pooled rates but do not prove transportability. The intervals omit uncertainty in the stipulated harm rates, practice clustering and transport.
* Every eligible patient is assumed reviewed, as the programme specifies. No pilot uptake multiplier was applied. The January pilot cohort does not reconstruct perfectly: 14 A/B review records concern people aged 64 at the stated search date.
* Annual benefit follows the specified formula. No additional six-month or April-to-December multiplier was applied; the estimates are not a dated operational rollout forecast.
* Historical activity covers all five networks, including Clun Valley. Clinical contact rows are treated as completed consultations because they lack attendance status. First receipt means first receipt evidenced in the supplied workflow; missing receipt dates were not imputed.
* Exact audit counts and denominators remain unrounded. Patient benefit estimates are rounded to the nearest 10, but rounding the underlying denominators would distort the requested activity rates.

Alternatives rejected.

* Choose B or C instead of A: both avoid fewer serious harms under the primary calculation, missing-follow-up analysis and age-standardized analysis.
* Choose C because it stops more medicines: C takes 460 patients off treatment versus A’s 240, but avoids 11 rather than 24 serious harms. The programme prioritizes harm reduction, not cessation volume.
* Use immediate “Stopped” decisions as success: the 53 subsequent reissues demonstrate why sustained cessation must be checked.
* Use repeat-course flags or ePACT totals for eligibility: `repeat_medication_courses_2026-12-31.csv` contains 16,547 courses, while `epact2_prescribing_summary_2025-26.xlsx` contains 672 aggregate rows. Neither replaces dated patient-level issue thresholds and clinical exclusions.
* Use falls admissions as a causal comparison: the 40-row admissions file shows Clun totals falling from 287 to 274, while non-Clun totals remain 935 in both years. This cannot separate the three simultaneous reviews or measure the full serious-harm outcome.
* Count raw activity rows: counting medicine lines would produce 24,021 rather than 18,826 letters. Exact references alone would miss 3,710 receipts. Adding consultation sources without reconciliation would double-count 1,165 hub contacts.

Files produced.

* `/home/agent/workspace/medicines_safety_review_2027.pdf`: five-page board paper containing the recommendation, runner-up and gap, paired benefit chart, historical activity rates, methods, sensitivity analysis and source audit.
* `/home/agent/workspace/pharmacist_consultations_2026.csv`: quarterly consultation counts, period-start registration denominators and one-decimal rates for every network.

Packages installed. Installed `pandas`, `pyarrow`, `pymupdf`, `openpyxl`, `matplotlib` and `reportlab`, with their dependencies, in a temporary virtual environment because they were unavailable in the active Python environment.
